keyword
MENU ▼
Read by QxMD icon Read
search

Sunitinib

keyword
https://www.readbyqxmd.com/read/28544544/insulin-like-growth-factor-1-signaling-is-responsible-for-cathepsin-g-induced-aggregation-of-breast-cancer-mcf-7-cells
#1
Riyo Morimoto-Kamata, Satoru Yui
Cathepsin G (CG), a neutrophil serine protease, induces cell migration and multicellular aggregation of human breast cancer MCF-7 cells in a process that is dependent on E-cadherin and CG enzymatic activity. While these tumor cell aggregates can cause tumor emboli that could represent intravascular growth and extravasation into the surrounding tissues, resulting in metastasis, the molecular mechanism underlying this process remains poorly characterized. In this study, we aimed to identify the signaling pathway that is triggered during CG-mediated stimulation of cell aggregation...
May 24, 2017: Cancer Science
https://www.readbyqxmd.com/read/28542880/suicidal-death-of-erythrocytes-in-cancer-and-its-chemotherapy-a-potential-target-in-the-treatment-of-tumor-associated-anemia
#2
REVIEW
Elisabeth Lang, Rosi Bissinger, Syed M Qadri, Florian Lang
In analogy to apoptosis of nucleated cells, erythrocytes may enter eryptosis characterized by cell shrinkage and cell membrane scrambling. Eryptotic erythrocytes are rapidly cleared from circulating blood and may adhere to the vascular wall. Stimulation of eryptosis thus impairs microcirculation and leads to anemia as soon as the loss of erythrocytes cannot be fully compensated by enhanced erythropoiesis. Signaling stimulating eryptosis includes increase of cytosolic Ca(2+) -activity, ceramide, caspases, calpain, p38-kinase, protein-kinase C, Janus-activated kinase 3, casein-kinase 1α, and cyclin-dependent kinase 4...
May 23, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28536740/-nivolumab-combined-with-ipilimumab-versus-sunitinib-monotherapy-sunniforecast-an-41-16-of-the-auo-a-phase-2-randomized-open-label-study-in-subjects-with-previously-untreated-and-advanced-unresectable-or-metastatic-non-clear-cell-renal-cell-carcinoma
#3
https://www.readbyqxmd.com/read/28536313/dual-inhibition-of-nox2-and-receptor-tyrosine-kinase-by-bj-1301-enhances-anticancer-therapy-efficacy-via-suppression-of-autocrine-stimulatory-factors-in-lung-cancer
#4
Jaya Gautam, Jin-Mo Ku, Sushil Chandra Regmi, Hyunyoung Jeong, Ying Wang, Suhrid Banskota, Myo-Hyeon Park, Tae-Gyu Nam, Byeong-Seon Jeong, Jung-Ae Kim
NADPH oxidase-derived reactive oxygen species (ROS) potentiate receptor tyrosine kinase (RTK) signalling, resulting in enhanced angiogenesis and tumor growth. In the present study, we report that BJ-1301, a hybrid of pyridinol and alpha-tocopherol, exerts anticancer effects by dual inhibition of NADPH oxidase and RTK activities in endothelial and lung cancer cells. BJ-1301 suppresses ROS production by blocking translocation of NADPH oxidase cytosolic subunits to the cell membrane, thereby inhibiting activation...
May 23, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28535693/experience-with-sunitinib-in-metastatic-renal-cell-carcinoma-mrcc-patients-pooled-analysis-from-3-spanish-observational-prospective-studies
#5
Daniel Castellano, José Pablo Maroto, Enrique Espinosa, Enrique Grande, Victoria Bolos, Julia Linares, Emilio Esteban, Aranzazu Gonzalez Del Alba, M A Climent, J A Arranz, Mª José Méndez, Eva Fernadez Parra, Luis Antón-Aparicio, Cristina Bayona, Isabel Gallegos, Enrique Gallardo, Luz Samaniego, J Garcia Donas
BACKGROUND: A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. OBJECTIVE: To evaluate the effectiveness and safety of sunitinib in patients with advanced or mRCC in routine clinical practice. METHODS: Retrospective pooled analysis of clinical data from three observational and prospective studies carried out between 2007 and 2011 in 33 Spanish hospitals...
May 24, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28531203/potential-health-gains-for-patients-with-metastatic-renal-cell-carcinoma-in-daily-clinical-practice-a-real-world-cost-effectiveness-analysis-of-sequential-first-and-second-line-treatments
#6
S De Groot, H M Blommestein, W K Redekop, S Sleijfer, L A L M Kiemeney, E Oosterwijk, C A Uyl-de Groot
INTRODUCTION: Randomised controlled trials have shown that targeted therapies like sunitinib are effective in metastatic renal cell carcinoma (mRCC). Little is known about the current use of these therapies, and their associated costs and effects in daily clinical practice. We estimated the real-world cost-effectiveness of different treatment strategies comprising one or more sequentially administered drugs. METHODS: Analyses were performed using patient-level data from a Dutch population-based registry including patients diagnosed with primary mRCC from January 2008 to December 2010 (i...
2017: PloS One
https://www.readbyqxmd.com/read/28529744/prognostic-effect-of-serum-c-reactive-protein-kinetics-on-advanced-renal-cell-carcinoma-treated-with-sunitinib
#7
Tetsuo Fujita, Ken-Ichi Tabata, Daisuke Ishii, Kazumasa Matsumoto, Kazunari Yoshida, Masatsugu Iwamura
C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the prognostic effect of pretreatment serum CRP level and CRP kinetics on patients with advanced RCC treated with sunitinib. A total of 56 consecutive patients with advanced RCC treated with sunitinib between December, 2008 and December, 2012 were enrolled in the present study. The patients were retrospectively divided into 3 cohorts according to pretreatment serum CRP level and CRP kinetics: i) Normal CRP cohort (pretreatment CRP ≤0...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28521783/association-of-post-treatment-hypoalbuminemia-and-survival-in-chinese-patients-with-metastatic-renal-cell-carcinoma
#8
Wen Cai, Jin Zhang, Yonghui Chen, Wen Kong, Yiran Huang, Jiwei Huang, Lixin Zhou
BACKGROUND: Hypoalbuminemia adversely affects the clinical outcomes of various cancers. The purpose of this study was to estimate the prognostic value of hypoalbuminemia 3-5 weeks after treatment in patients with metastatic renal cell carcinoma (mRCC) who received sorafenib or sunitinib as first-line treatment. METHODS: In this single-center, retrospective study, we assessed the progression-free survival (PFS) and overall survival (OS) of 184 mRCC patients who received first-line sorafenib or sunitinib treatment...
May 18, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28515920/predictive-value-of-the-modified-glasgow-prognostic-score-for-the-therapeutic-effects-of-molecular-targeted-drugs-on-advanced-renal-cell-carcinoma
#9
Hirofumi Ohmura, Keita Uchino, Tatsuhiro Kajitani, Naotaka Sakamoto, Eishi Baba
Inflammation is considered to be a prognostic factor for renal cell carcinoma (RCC). An inflammation-based prognostic score (modified Glasgow Prognostic Score; mGPS) is widely used for preoperative patients; however, little information is available regarding its prognostic value in patients with RCC treated with molecular-targeted drugs. A total of 32 advanced and recurrent RCC patients initially treated with molecular-targeted drugs from October, 2009 to August, 2015 were retrospectively investigated. Information on patient characteristics prior to treatment initiation and the clinical course were retrieved from clinical records...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28515811/first-line-sunitinib-or-pazopanib-in-metastatic-renal-cell-carcinoma-the-canadian-experience
#10
Aly-Khan A Lalani, Haocheng Li, Daniel Y C Heng, Lori Wood, Austin Kalirai, Georg A Bjarnason, Hao-Wen Sim, Christian K Kollmannsberger, Anil Kapoor, Sebastien J Hotte, Marie Vanhuyse, Piotr Czaykowski, M Neil Reaume, Denis Soulieres, Peter Venner, Scott North, Naveen S Basappa
INTRODUCTION: Clinical trial data has shown pazopanib to be non-inferior in overall survival (OS) compared to sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC). The purpose of this study was to evaluate outcomes and compare dose-modifying toxicities of mRCC patients treated with suntinib or pazopanib in the real-world setting. METHODS: Data were collected on mRCC patients using the prospective Canadian Kidney Cancer Information System (CKCis) database from January 2011 to November 2015...
March 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28515249/incorporating-new-systemic-therapies-in-kidney-cancer-treatment
#11
Eric Jonasch
In 2017, pazopanib and sunitinib remain the mainstays of frontline therapy for advanced renal cell carcinoma. Independent review of frontline cabozantinib therapy may alter standard of care for patients at intermediate and poor risk. Multiple agents show a survival advantage in the second-line setting, including nivolumab, cabozantinib, and combination lenvatinib and everolimus. Selection of subsequent therapy will depend on patient disease status, comorbidities, and resource availability.
May 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28504837/immunotherapy-for-metastatic-renal-cell-carcinoma
#12
REVIEW
Susanne Unverzagt, Ines Moldenhauer, Monika Nothacker, Dorothea Roßmeißl, Andreas V Hadjinicolaou, Frank Peinemann, Francesco Greco, Barbara Seliger
BACKGROUND: Since the mid-2000s, the field of metastatic renal cell carcinoma (mRCC) has experienced a paradigm shift from non-specific therapy with broad-acting cytokines to specific regimens, which directly target the cancer, the tumour microenvironment, or both.Current guidelines recommend targeted therapies with agents such as sunitinib, pazopanib or temsirolimus (for people with poor prognosis) as the standard of care for first-line treatment of people with mRCC and mention non-specific cytokines as an alternative option for selected patients...
May 15, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28500677/optimizing-the-dose-in-cancer-patients-treated-with-imatinib-sunitinib-and-pazopanib
#13
N A G Lankheet, I M E Desar, S F Mulder, D M Burger, D M Kweekel, C M L van Herpen, W T A van der Graaf, N P van Erp
AIM: Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high interpatient variability in plasma exposure. A relationship between plasma exposure and treatment outcome has been established, which supports the rationale for dose optimization of these drugs. The aim of this study was to monitor how many patients reached adequate trough levels after therapeutic drug monitoring (TDM) based dose optimization in daily practice. METHODS: A cohort study was performed in patients treated with imatinib, sunitinib or pazopanib of whom follow-up drug levels were measured between August 2012 and April 2016...
May 12, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28499874/pyrrole-indolinone-su11652-targets-the-nucleoside-diphosphate-kinase-from-leishmania-parasites
#14
Plínio Salmazo Vieira, Tatiana de Arruda Campos Brasil Souza, Rodrigo Vargas Honorato, Letícia Maria Zanphorlin, Kelven Ulisses Severiano, Silvana Aparecida Rocco, Arthur Henrique Cavalcante de Oliveira, Artur Torres Cordeiro, Paulo Sérgio Lopes de Oliveira, Priscila Oliveira de Giuseppe, Mário Tyago Murakami
Nucleoside diphosphate kinases (NDKs) are key enzymes in the purine-salvage pathway of trypanosomatids and have been associated with the maintenance of host-cell integrity for the benefit of the parasite, being potential targets for rational drug discovery and design. The NDK from Leishmania major (LmNDK) and mutants were expressed and purified to homogeneity. Thermal shift assays were employed to identify potential inhibitors for LmNDK. Calorimetric experiments, site-directed mutagenesis and molecular docking analysis were performed to validate the interaction and to evaluate the structural basis of ligand recognition...
May 9, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28495808/comprehensive-genomic-profiling-of-esthesioneuroblastoma-reveals-additional-treatment-options
#15
Laurie M Gay, Sungeun Kim, Kyle Fedorchak, Madappa Kundranda, Yazmin Odia, Chaitali Nangia, James Battiste, Gerardo Colon-Otero, Steven Powell, Jeffery Russell, Julia A Elvin, Jo-Anne Vergilio, James Suh, Siraj M Ali, Philip J Stephens, Vincent A Miller, Jeffrey S Ross
BACKGROUND: Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses with rapid progression. Current multimodality, nontargeted therapy for relapsed ENB is of limited clinical benefit. MATERIALS AND METHODS: We queried whether comprehensive genomic profiling (CGP) of relapsed or refractory ENB can uncover genomic alterations (GA) that could identify potential targeted therapies for these patients...
May 11, 2017: Oncologist
https://www.readbyqxmd.com/read/28491276/antiangiogenic-effects-in-patients-with-progressive-desmoplastic-small-round-cell-tumor-data-from-the-french-national-registry-dedicated-to-the-use-of-off-labeled-targeted-therapy-in-sarcoma-outc-s
#16
Sarah Bétrian, Christophe Bergeron, Jean-Yves Blay, Emmanuelle Bompas, Philippe A Cassier, Laure Chevallier, Jérome Fayette, Magali Girodet, Cécile Guillemet, Axel Le Cesne, Perrine Marec-Berard, Isabelle Ray-Coquard, Christine Chevreau
BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a very rare mesenchymal tumor that mainly affects teenagers and young adults with a mean age at diagnosis around 20-25 years. Although initial management still needs standardization, many centers will use multimodal treatment including intensive chemotherapy, extensive surgical resection followed by radiotherapy. Despite this, prognosis remains very poor and the median overall survival is 25 months. Recurrent disease is mainly treated by chemotherapy...
2017: Clinical Sarcoma Research
https://www.readbyqxmd.com/read/28487491/a-phase-ii-trial-of-regorafenib-in-patients-with-metastatic-and-or-a-unresectable-gastrointestinal-stromal-tumor-harboring-secondary-mutations-of-exon-17
#17
Chun-Nan Yeh, Ming-Huang Chen, Yen-Yang Chen, Ching-Yao Yang, Chueh-Chuan Yen, Chin-Yuan Tzen, Li-Tzong Chen, Ji-Shi Chen
BACKGROUND: Gastrointestinal stromal tumors (GISTs) are caused by the constitutive activation of KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations. Imatinib selectively inhibits KIT and PDGFR, leading to disease control for 80%-90% of patients with metastatic GIST. Imatinib resistance can occur within a median of 2-3 years due to secondary mutations in KIT. According to preclinical studies, both imatinib and sunitinib are ineffective against exon 17 mutations. However, the treatment efficacy of regorafenib for patients with GIST with exon 17 mutations is still unknown...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28479237/adjuvant-therapy-for-high-risk-localized-kidney-cancer-emerging-evidence-and-future-clinical-trials
#18
REVIEW
Andrew T Lenis, Nicholas M Donin, David C Johnson, Izak Faiena, Amirali Salmasi, Alexandra Drakaki, Arie Belldegrun, Allan Pantuck, Karim Chamie
PURPOSE: We will review the literature on adjuvant therapies for patients with high-risk localized kidney cancer following surgical treatment. Two recently published prospective trials with conflicting results will be reconciled within the context of their respective designs. Finally, we will spotlight upcoming trials that use novel immunotherapy-based checkpoint inhibitors and have the potential to establish a new standard of care. MATERIALS AND METHODS: A PubMed search was performed for English language articles using the keywords "renal cell carcinoma," "kidney cancer," "immunotherapy," "targeted therapy," and "adjuvant therapy" published through January 2017...
May 4, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28477178/antiangiogenics-and-immunotherapies-in-cervical-cancer-an-update-and-future-s-view
#19
REVIEW
Daniela Luvero, Francesco Plotti, Salvatore Lopez, Giuseppe Scaletta, Stella Capriglione, Roberto Montera, Gianina Antonelli, Sara Ciuffreda, Raffaella Carassiti, Alice Oliveti, Roberto Angioli
Despite availability of primary and secondary prevention measures, cervical cancer (CC) persists as one of the most common cancers among women around the world, and more than 70% of cases are diagnosed at advanced stages. Although significant progress has been made in the treatment of CC, around 15-61% of patients develop a recurrence in lymph nodes or distant sites within the first 2 years of completing treatment and the prognosis for these patients remains poor. During the last decades, in an attempt to improve the outcome in these patients, novel agents as combination therapy that target known dysfunctional molecular pathways have been developed with the most attention to the inhibitors of the angiogenesis process...
June 2017: Medical Oncology
https://www.readbyqxmd.com/read/28466375/impressive-and-durable-response-to-nivolumab-in-a-patient-with-metastatic-type-2-papillary-renal-cell-carcinoma-on-label-but-without-evidence
#20
Diego A Adrianzen Herrera, Sarah B Fleisig, Benjamin A Gartrell
Nivolumab is a treatment option for patients with metastatic renal cell carcinoma (RCC) previously treated with targeted antiangiogenic therapy. Papillary renal cell carcinoma (PRCC) comprises 10-15% of RCC cases but non-clear cell subtypes were excluded from the immunotherapy trials. We report the case of a woman with recurrent metastatic PRCC who had an impressive therapeutic response to nivolumab with no significant adverse events. She had previously been treated with sunitinib and pazopanib with no response...
May 2, 2017: Investigational New Drugs
keyword
keyword
21148
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"